Full Genomes Corp

ROCKVILLE, MD · Founded 2012 · Biotech · Private

High-definition DNA sequencing platform for personalized medication, nutrition, and skincare recommendations based on genetic analysis

Claim this profile

Follows are private to you and power your alerts

Updated · fullgenomes.us

Sector
Biotech
Headquarters
ROCKVILLE, MD
Founded
2012
Latest Form D
$25K, Mar 2019
Total capital
$622K
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$612K
8 Form D · last Mar 2019
92 months since last filing
Federal contracts
$10K
1 award · Justice
Rank in Biotech#384 of 4373
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

2013201420152016201720182019FEDERAL ↑EQUITY ↓Cumulative $622K$10K1st Form D$250K6th Form D$100K8th Form D$25K
2013201520172019FEDERAL ↑EQUITY ↓Cumulative $622K$10K

Latest events

  • Private capital raisedForm D · SEC · 8th filing$25K
  • Private capital raisedForm D · SEC · 7th filing$188K
  • Private capital raisedForm D · SEC · 6th filing$100K
  • Private capital raisedForm D · SEC · 5th filing$19K
  • Private capital raisedForm D · SEC · 4th filing$10K
  • Private capital raisedForm D · SEC · 3rd filing$10K
  • Federal contractJustice · Whole Y Chromosome Sequencing (igf::ct::igf)$10K
  • Private capital raisedForm D · SEC · 2nd filing$10K
  • Private capital raisedForm D · SEC · 1st filing$250K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Abdullah MarafiDirectorNamed in SEC Form D filings
  • Ian Allen BurbulisDirectorNamed in SEC Form D filings
  • Justin Allen LoeExecutive OfficerNamed in SEC Form D filings
  • Leon KullDirectorNamed in SEC Form D filings
  • Nicolas Allen TabanDirectorNamed in SEC Form D filings
  • Nong Allen ChenExecutive Officer, DirectorNamed in SEC Form D filings
Show all 7 people
  • Paul ConroyDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • SPECTRAGENETICSSimilar federal contract value in Biotech · $11K in contracts
  • Infinity Bio, Inc.Similar federal contract value in Biotech · $11K in contracts
  • seqWell Inc.Similar federal contract value in Biotech · $10K in contracts
  • Cellecta, IncorporatedSimilar federal contract value in Biotech · $9K in contracts
  • Zenobia Therapeutics, Inc.Similar federal contract value in Biotech · $8K in contracts
  • RADIOMEDIX, INC.Similar federal contract value in Biotech · $5K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .